Annunziata G, Verde L, Tarsitano MG, Stallone T, Grillo ARA, Santaniello MG, et al
It has been shown to help obese and overweight people with type 2 diabetes lose 11% of their body weight after 72 weeks on the 36mg dose
Retatrutide is the first triple-agonist GLP-1/GIP/Glucagon medication in Phase 3 trials, made by Eli Lilly
From Indio, head west and we're on the left
Crystals 13:648 Bailey CJ, Flatt PR, Conlon J (2023) An update on peptide-based therapies for type 2 diabetes and obesity
It is important to note that the digestive side effects of semaglutide, while notable, are typically manageable